Company (Symbol)* |
Product |
Description | Indication |
Status/Date** |
CANCER | ||||
Cel-Sci Corp. | Multikine (AMEX:HIV) |
Natural mixture of human cytokines, including interleukin-2 | Head and neck cancer |
The company reported that independent investigators completed enrollment of a 28-patient clinical study in Canada (11/8) |
Corixa Corp. (CRXA) | Melacine | Melanoma therapeutic vaccine | Late-stage melanoma | Canadian Health Protection Branch issued a notice of compliance, approving Melacine for sale in Canada (11/4) |
Ligand Pharmaceuticals Inc. (LGND) |
Targretin capsules | Bexarotene; synthetic retinoid X receptor's; oral formulation | Cutaneous T-cell lymphoma | Submitted a marketing authorization application (MAA) with the European Medicines Evaluation Agency (EMEA) (11/29) |
OxiGene Inc. (Sweden; SSE:OXGN) | Combretastatin A4 Prodrug (CA4P) |
Angiogenic inhibitor that attacks pre-existent tumor |
Patients with advanced vasculature malignancies | Reported Phase I results at the annual Mount Sinai Medical Center Chemotherapy Foundation Symposium XVII (11/5) |
CENTRAL NERVOUS SYSTEM | ||||
NeoTherapeutics Inc. (NEOT) | Neotrofin | Small-molecule compound designed to cross blood-brain barrier and enhance nerve cell function by increasing levels of neutrophic factors |
Alzheimer's disease | Announced interim Phase IIb results from study conducted in Canada, Australia and the Republic of South Africa (11/30) |
INFECTION | ||||
BioChem Pharma Inc. (BCHE) |
Zeffix (FDA-approved) |
Lamivudine; nucleoside analogue (oral dosage) | Chronic hepatitis B |
Approved in Taiwan (11/1) |
Cantab Pharmaceuticals plc (UK; LSE:CTB) |
| Herpes vaccine | Genital herpes |
Began vaccination for Phase II trials (11/4) |
Enzon Inc. (ENZN) and Schering Plough Corp. (NYSE:SGP) | Peg-Intron |
Long-acting dosage form of Intron A (recombinant interferon alfa-2b) conjugated to polyethylene glycol | Chronic hepatitis C | Submitted MAA to the EMEA (11/9) |
Hollis-Eden Pharmaceuticals Inc. (HEPH) |
HE2000 | Cell-energy regulator that works on host cells | HIV infection |
Announced Phase I/II results from clinical trial in South Africa (11/3) |
The Immune Response Corp. (IMNR) |
Remune | Envelope-depleted, inactivated AIDS virus (emulsified with adjuvant) | HIV infection | Data Safety and Monitoring Board recommended that trial in Spain continue to conclusion (11/4) |
The Liposome Co. (LIPO) |
Abelcet | Amphotericin B lipid complex injection |
Invasive fungal infections in patients refractory to or intolerant of conventional amphotericin B therapy |
Received marketing approval in Turkey (11/2) |
PowderJect Pharmaceuticals plc (UK; LSE:PJP) | DNA vaccines delivered via PowderJect System |
Needle-free injection system |
Malaria | Reported clinical results at the American Society of Tropical Medicine and Hygiene 48th Annual Meeting (11/29) |
MISCELLANEOUS | ||||
Amgen Inc. (AMGN) | Novel Erythropoiesis Stimulating Protein (NESP) | Molecule with a prolonged biological half-life that stimulates production of red blood cells | Hemodialysis and peritoneal dialysis patients | Announced Phase III results at the annual meeting of the American Society of Nephrology (11/7) |
BioTime Inc. (AMEX:BTX) |
Hextend |
Physiologically compatible blood plasma expander |
Hypovolemia resulting from surgical procedures and injuries | New drug submission accepted by the Canadian Health Protection Branch (11/5) |
Protein Design Labs Inc. (PDLI) | SMART Anti-L-Selectin Antibody |
Humanized monoclonal antibody |
Multiple trauma with injuries involving two or more organ systems | Initiated Phase IIa international trial (11/16) |
QLT PhotoTherapeutics Inc. (QLTI) and Ciba Vision Corp. (a unit of Novartis AG) | Visudyne | Verteporfin; light-activated drug for photodynamic | Wet age-related macular degeneration therapy | Filed for approval with the Canadian Therapeutics Products Programme (11/4) |
Notes: | ||||
This chart is intended to provide a monthly update on the clinical and regulatory status of biotech and biotech-related products in development in countries other than the U.S., whether those products are being developed by U.S.-based or non-U.S.-based firms. It covers only those events that were announced in 10/99. It does not cover ongoing clinical trials for which no news was issued that month. | ||||
* Indicates a privately held company. | ||||
** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SSE = Swedish Stock Exchange; TSE = Toronto Stock Exchange | ||||
ND = Not Disclosed | ||||
